Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Jun-Hyung | - |
dc.contributor.author | Jin, So Young | - |
dc.contributor.author | Park, Suyeon | - |
dc.date.accessioned | 2022-06-09T02:49:48Z | - |
dc.date.available | 2022-06-09T02:49:48Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 1478-7210 | - |
dc.identifier.issn | 1744-8336 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/20988 | - |
dc.description.abstract | Objectives: We aimed to compare the success rate, adverse drug events, and cost-effectiveness of tailored Helicobacter pylori eradication and modified bismuth-containing quadruple therapy. Methods: The diagnosis of H. pylori infection was randomly based on either rapid urease test (RUT) or dual priming oligonucleotide (DPO)-based multiplex polymerase chain reaction (PCR) in 1:1 ratio. According to the presence of point mutations that cause clarithromycin resistance, patients in the tailored therapy (TT) group received standard triple therapy or classic bismuth quadruple therapy. Patients with positive RUT results received 40 mg pantoprazole, 1000 mg amoxicillin, 750 mg metronidazole, and 600 mg bismuth subcitrate twice daily for 14 days (PAM-B therapy). Results: Between the TT (n = 141) and PAM-B groups (n = 141), H. pylori eradication rate did not differ significantly according to intention-to-treat (TT: 80.9% vs. PAM-B: 85.8%, P = 0.262), modified intention-to-treat (TT: 89.1% vs. PAM-B: 91.0%, P = 0.606), and per-protocol (TT: 89.0% vs. PAM-B: 93.5%, P = 0.198) analyses. The average cost for successful eradication was higher in the TT group than in the PAM-B group ($340.7 vs. $263.9 per patient). Conclusion: PAM-B therapy exhibits similar efficacy and improved cost-effectiveness compared to TT based on the results of DPO-PCR tests. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Future Drugs Ltd. | - |
dc.title | Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1080/14787210.2022.2017280 | - |
dc.identifier.scopusid | 2-s2.0-85121727923 | - |
dc.identifier.wosid | 000734215300001 | - |
dc.identifier.bibliographicCitation | Expert Review of Anti-Infective Therapy, v.20, no.6, pp 923 - 929 | - |
dc.citation.title | Expert Review of Anti-Infective Therapy | - |
dc.citation.volume | 20 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 923 | - |
dc.citation.endPage | 929 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | TRIPLE THERAPY | - |
dc.subject.keywordPlus | ANTIMICROBIAL RESISTANCE | - |
dc.subject.keywordPlus | CLARITHROMYCIN | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | AMOXICILLIN | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.subject.keywordAuthor | eradication | - |
dc.subject.keywordAuthor | clarithromycin resistance | - |
dc.subject.keywordAuthor | bismuth | - |
dc.subject.keywordAuthor | metronidazole | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.